Jeffrey Garner, MD
Pulmonary Disease · Birmingham, ALNPI 1467686303
Payments from drug & device makers
Across 527 payments — averaging $26.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$2K
- AstraZeneca$1K
- Boehringer Ingelheim$827
- Mallinckrodt Hospital Products Inc.$766
- Regeneron Healthcare Solutions, Inc.$609
- plus $4K from 35 others
What the payments were for
- Travel & lodging$1,38210%
- Food & beverage$9,83369%
- Education$3,00021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $4,450 |
| GSK | 125 | $2,094 |
| AstraZeneca | 59 | $1,043 |
| Boehringer Ingelheim | 41 | $827 |
| Mallinckrodt Hospital Products Inc. | 35 | $766 |
| Regeneron Healthcare Solutions, Inc. | 31 | $609 |
| Grifols USA, LLC | 26 | $540 |
| Genentech USA, Inc. | 21 | $413 |
| Amgen | 20 | $312 |
| Philips North America LLC | 15 | $297 |
| Merck | 16 | $285 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $271 |
| Gilead | 13 | $236 |
| CSL Behring | 8 | $221 |
| United Therapeutics Corporation | 10 | $212 |
| Mylan Specialty L.p. | 10 | $177 |
| Insmed, Inc. | 9 | $173 |
| Johnson & Johnson(2 entities) | 6 | $156 |
| Sanofi | 7 | $132 |
| Mallinckrodt Enterprises LLC | 7 | $122 |
| Vifor Pharma, Inc. | 5 | $111 |
| ANI Pharmaceuticals, Inc. | 4 | $91 |
| Jazz Pharmaceuticals Inc. | 4 | $84 |
| Astellas Pharma US Inc | 4 | $71 |
| Pfizer | 4 | $70 |
| Inogen, Inc. | 3 | $62 |
| Harmony Biosciences LLC | 2 | $49 |
| Varian Medical Systems, Inc. | 1 | $47 |
| Pulmonx Corporation | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Electromed, Inc. | 3 | $33 |
| Avanos Medical | 1 | $31 |
| Cook Medical LLC | 2 | $23 |
| Viatris Specialty LLC | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| AbbVie | 1 | $17 |
| Shionogi Inc | 1 | $15 |
| 3b Medical, Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,186
How this compares
$14,215 in reported general payments places this provider in the 80th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 375 | $287,505 |
| Breo ElliptaFluticasone/Vilanterol | 124 | $57,779 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $33,828 |
| Spiriva RespimatTiotropium Bromide | 30 | $18,344 |
| EliquisApixaban | 17 | $10,936 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $9,396 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $7,967 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 268 | $6,016 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,738 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $4,672 |
| Theo-24Theophylline Anhydrous | 14 | $4,655 |
| Wixela InhubFluticasone Propion/Salmeterol | 35 | $4,276 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $4,105 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,641 |
| Azithromycin | 86 | $1,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,094 | $354,664523 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,043 | $43,22494 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $827 | $26,31147 claims |
| PfizerEliquis | $70 | $10,93617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Birmingham
- Tejaswini KulkarniBirmingham$1.7M
- Bryan GarciaBirmingham$606K
- Veena AntonyBirmingham$327K
- Steven RoweBirmingham$252K
- Derek RussellBirmingham$190K
- Raymond WadeBirmingham$135K
- Joseph Thachuthara-GeorgeBirmingham$126K
- Jennifer TrevorBirmingham$99K
- Peter MorrisBirmingham$94K
- Amanda DenhamBirmingham$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.